Societies

The efficacy benefits of radioisotopes in metastatic castration-resistant prostate cancer – ESMO

Photo taken from ESMO/LinkedIn

Sep 16, 2024, 10:25

The efficacy benefits of radioisotopes in metastatic castration-resistant prostate cancer – ESMO

ESMO shared on LinkedIn:

“At ESMO24, Late-Breaking Abstracts provide evidence for the efficacy benefits of radioisotopes, radium (Ra)-223 and 177Lu-PNT2002, in metastatic castration-resistant prostate cancer (mCRPC). In the PEACE-3 trial, radiological PFS and OS (interim analysis) were longer with Ra-223 plus enzalutamide versus enzalutamide alone in patients with mCRPC and bone metastases. Initial radiological PFS results appeared encouraging for 177Lu-PNT2002 in PSMA-positive mCRPC after progression.

The final results are eagerly anticipated, according to Karim Fizazi, who provides insights on these findings on the ESMO Daily Reporter.”

Read Further.
Source: ESMO/LinkedIn

More posts featuring ESMO24 on oncodaily.com

cancer ESMO ESMO Daily Reporter Karim Fizazi late breaking abstracts metastatic castration-resistant prostate cancer OncoDaily Oncology radiation oncology radioscopy

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage